Based on Nuance’s Dragon Medical platform already used by over 550,000 physicians, DAX Copilot leverages conversational, ambient, and generative AI to further the company’s position in delivering market leading AI-powered solutions for healthcare and life sciences
BURLINGTON, Mass., Sept. 27, 2023 /PRNewswire/ — Nuance Communications, Inc., a Microsoft Company, today announced the general availability of Dragon Ambient eXperience (DAX™) Copilot, formerly known as DAX Express. Serving as an AI copilot for automated clinical documentation, the application uses conversational, ambient, and generative AI to enable more physicians to significantly streamline the creation of medical documentation, improving clinical efficiency, reducing burnout, and freeing their time to focus on delivering high-quality care.
Morgan Stanley predicts AI investment in healthcare will jump to nearly 11% in 2024, compared to 5.7% in 2022. U.S. health systems are rapidly turning to AI-powered solutions to improve clinical efficiency and alleviate clinician burnout caused by heavy administrative workloads. According to a recent Medscape survey, the number of physicians reporting feelings of burnout rose to 53% in 2023, up from 42% in 2018. DAX Copilot automatically and securely creates draft clinical summaries of exam room or telehealth conversations in seconds for immediate physician review and entry in the electronic health record (EHR) system. Amplified by the power and scale of the Microsoft Cloud for Healthcare, DAX Copilot combines Nuance’s proven conversational and ambient AI with the newest and most capable generative AI model to improve clinical efficiency and enable clinicians to spend more time caring for patients.
“Over the past four years, Microsoft has worked with partners like OpenAI to hone the power of generative AI to improve outcomes and experiences for all users. As a result, Microsoft is heralding a new and exciting era of AI-powered copilots to assist humans across industries, including doctors and nurses, with complex cognitive tasks,” said Diana Nole, Executive Vice President and General Manager of Healthcare at Nuance, a Microsoft company. “Healthcare is one of the biggest areas of potential for copilots given the tremendous administrative burden placed on clinicians and other medical staff. Taking a responsible approach to AI that centers around unparalleled collaboration with the world’s top AI researchers and access to a trusted infrastructure and global platform, Nuance is arming healthcare providers with a trusted copilot that enables them with more time to take care of their patients.”
Nuance has decades of experience developing AI-powered healthcare solutions used by hundreds of thousands of clinicians that are proven to consistently deliver value and outcomes for physicians, nurses, radiologists, and patients. Nuance has long been at the forefront of innovating conversational and ambient AI in healthcare – most notably with Dragon Medical One and most recently with DAX – and for years has leveraged expertise in large language models, natural language processing, and clinical workflows and needs to deliver refined, trusted AI solutions around the globe.
Dragon Medical One is a Best in KLAS three years running cloud-based speech recognition solution that acts as a workflow assistant and documentation companion to document clinical visits in the EHR. Dragon Medical One, used by more than 550,000 users worldwide, provides clinicians with the ability to use their voices to capture the patient story efficiently and securely, more naturally navigate key clinical systems, and easily access information to facilitate patient care. It is known for its accuracy, reliability, and tight integration with the EHR.
DAX Copilot is part of the larger Nuance Dragon family of solutions, which are currently deployed across hundreds of healthcare organizations and used by thousands of clinicians, resulting in a 70% reduction in feelings of burnout and fatigue, 50% less time spent on documentation, 7 minutes saved per encounter, and 5 additional appointments added on average per clinic day. DAX Copilot provides an immediate and highly accessible entry point for healthcare organizations to adopt at scale a new generation of AI-powered clinical documentation applications, leveraging their existing investments in the trusted Nuance Dragon Medical platform. Clinicians using DAX Copilot in a private preview have reported that it has helped them achieve a better work-life balance, higher job satisfaction, more focused, personable, and conversational patient visits, and reduced feelings of burnout and cognitive load. In a survey of clinicians using DAX Copilot, almost three-quarters say that it has led to a better experience providing care, and 96% agree it is easy to use.
For more information about Nuance DAX Copilot, please visit: nuance.com/DAXCopilot. To see DAX Copilot in action, or to learn more about Nuance, connect with us at HLTH, October 8-11 in Las Vegas.
About Nuance Communications Nuance Communications is a technology pioneer with market leadership in conversational, ambient, and generative AI. A full-service partner trusted by 77 percent of U.S. hospitals and more than 75 percent of the Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people’s ability to help others. Nuance is a Microsoft company.
Trademark reference: Nuance and the Nuance logo are registered trademarks or trademarks of Nuance Communications, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.
POTOMAC, Md., Sept. 27, 2023 /PRNewswire/ — Get ready to taco ’bout a delicious celebration at California Tortilla, the “California Style” Mexican food franchise! The brand is celebrating National Taco Day on October 4 by giving away a free taco coupon with any in-store purchase. The free taco offer is good in-store only while supplies last.
“We take pride in our reputation of crafting bold, diverse flavors, and our tacos have consistently remained fan favorites,” said Robert Phillips, President of California Tortilla. “We all know tacos are one of America’s favorite food items and we are thrilled to offer our valued guests the taste of a complimentary taco.”
Guests can redeem their free taco coupon from October 5 – 11, 2023. California Tortilla encourages guests to continue heading towards free menu items by joining their Burrito Elito rewards program and earning 1 point for every dollar spent. After accumulating 75 points, guests can earn $5 in Burrito Bucks. Joining is easy – guests can download the mobile app (App Store or Google Play), pick up a card in-store and register it online, or simply join online and give the cashier your phone number on each visit for easy lookup.
California Tortilla is known for its innovative menu, featuring unique chef-created recipes like mouthwatering Korean BBQ and California Sunset tacos. Every California Tortilla features a Wall-of-Flame, a towering display of 75 distinct hot sauces, ranging from mild to tongue-melting, allowing guests to customize their meal’s flavor and heat level. The locations offer dine-in, online ordering, and delivery.
For more information, visit www.californiatortilla.com or follow them on Instagram and Twitter @CalTort.
About California Tortilla® California Tortilla® is a unique fast casual restaurant franchise that serves “California style” Mexican food. Since 1995, California Tortilla, adoringly known by fans as Cal Tort, has brought a fresh perspective to Mexican food through offering bold and exciting flavor profiles, while offering only the best quality. With 41 locations, the Chef-Inspired menu continues to delight customers throughout the United States.
California Tortilla is seeking experienced multi-unit operators who are interested in diversifying and growing their restaurant portfolios. Current growth opportunities are available in the eastern half of the United States.
NEW YORK, Sept. 27, 2023 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Holly Energy Partners, L.P. (NYSE: HEP)’s sale to HF Sinclair Corporation for 0.315 shares of HF Sinclair common stock and $4.00 in cash, without interest, for each publicly held common unit of Holly Energy. If you are a Holly Energy shareholder, click here to learn more about your rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
–Researchers found exposing cells to a small molecule drug improved their fitness during hematopoietic stem cell transplants, which could broaden access and improve outcomes for ex vivo gene therapy–
PHILADELPHIA, Sept. 27, 2023 /PRNewswire/ — A readily available, inexpensive small molecule drug can improve the fitness of hematopoietic stem and progenitor cells (HSPCs) that are modified outside of the body, potentially improving the success of procedures like ex vivo gene therapy, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP). The study, published in the journal Blood, showed that targeting components in the cells called extracellular vesicles (EVs) relieves the stress on cells when outside of the body, improving their performance when they are transplanted back inside.
“We initially embarked on this project to better understand the role of these vesicles, assuming – wrongly, as it turns out – that blocking their function would have detrimental effects on the cells,” said first author Stephanie Hurwitz, MD, PhD, a research fellow in the Kurre Lab at CHOP and Hematopathologist at the University of Pennsylvania. “We discovered the opposite is true: blocking the formation of these vesicles over a relatively short period of time actually improved the cells’ fitness, initiating an adaptive stress response that protects them from the stress of being outside of the body. Ultimately, this serendipitous finding could enhance the quality of transplant products used in treatments like ex vivo gene therapy, improving patient outcomes.”
Hematopoietic stem cell transplantation (HSCT) involves the transfer of HSPCs from a donor to patients with both benign and malignant diseases. In some cases, as in ex vivo gene therapy, the patient acts as their own donor: the patient’s HSPCs are removed, modified outside of the body using gene addition or gene editing, and then transplanted back in. When enough cells are available for modification, this strategy has proven to be a powerful platform for treating genetic blood disorders, including sickle cell disease and beta thalassemia.
However, maintaining the fitness of these cells outside of the body poses a challenge, and any loss of fitness introduces the risk that the cells will not properly restore the blood and immune cell system in patients. For this reason, researchers have sought to better understand HSPC programming and signaling so that every attempt could be made to maintain cell health ahead of transplant.
One process that we now learn contributes to cell equilibrium is the secretion of EVs, which are important for delivering messages from cell to cell and maintaining proper cell function. However, technical challenges have previously prevented researchers from fully understanding the role these EVs might play in HSPC fitness outside of the body.
To explore the role of EVs, the researchers exposed both mouse and human HSPCs to GW4869, a readily available small molecule drug that blocks neutral sphingomyelinase-2 (nSMase2), an enzyme involved in EV formation. The researchers found that an exposure of 24 hours led to sustained improvements in cell fitness and transplantation efficiency after ex vivo culture, with improved rates of blood cell function in mouse models.
Additionally, the researchers found that blocking nSMase2 in human CD34+ cells leveled disparities in how well the cells of varying HLA types performed after transplantation into mice. This is of particular interest given important role of HLA in long-term transplantation outcomes.
Drilling down on the mechanisms behind these phenomena, the researchers determined that blocking nSMase2 activates an integrated stress response, effectively putting the cells into a state of quiescence, where they are protected from external stressors. This occurs due, in part, from GW4869 disrupting sphingolipid metabolism, which impairs the release of nSMase2-dependent EVs.
“While numerous advances have been made over past decades to improve safety and efficiency of HSPC transplantation and ex vivo gene therapy, constraints in cell quantity and graft success continue to limit outcomes,” said senior author Peter Kurre, MD, Director of the Pediatric Comprehensive Bone Marrow Failure Center at CHOP. “This important study, which links EV trafficking and the integrated stress response as a regulatory dyad guarding HSPC integrity and long-term fitness, has important implications for potentially broadening patient eligibility to ex vivo gene therapies. Researchers should continue to explore the potential of this small molecule drug in improving ex vivo HSPC culture and transplantation.”
This research was supported by NIH grants R01-HL164633, 4-R38-HL143613-04 , T32 HL-07439, and P30ES013508. The analyses were made possible through collaboration with the CHOP Flow Cytometry core laboratory, CHOP Department of Veterinary Resources, University of Pennsylvania Stem Cell and Xenograft Core, University of Pennsylvania Hematopoietic Stem Cell Laboratory, CHOP-PENN Proteomics Core Facility, and CHOP Center for Applied Genomics core laboratory.
Hurwitz et al. “Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response,” Blood, online Sept. 12, 2023, DOI: 10.1182/blood.2023022147
About Children’s Hospital of Philadelphia: A non-profit, charitable organization, Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the 595-bed hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as an inpatient hospital with a dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children’s Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.
Contact: Jennifer Lee Children’s Hospital of Philadelphia (267) 426-6084 [email protected]
NEW YORK, Sept. 27, 2023 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Hostess Brands, Inc. (NASDAQ: TWNK)’s sale to The J.M. Smucker Co. for $30.00 in cash and 0.03002 shares of J.M. Smucker common stock for each share of Hostess Brands common stock. If you are a Hostess Brands shareholder, click here to learn more about your rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
TORONTO, Sept. 27, 2023 /PRNewswire/ – Kognitiv Corporation (“Kognitiv”) delivers AI-powered loyalty and data activation solutions to enable highly effective personalization and optimization of the customer experience. Kognitiv is thrilled to add Kognitiv Ignite to its innovative, omni-channel SaaS platform. This transformative AI-native, outcome-based, one-to-one personalization software has been designed to reshape and propel brands’ customer engagement strategies across owned channels.
Kognitiv Ignite changes the way brands approach customer engagement across owned channels by enabling marketers to begin with the end goals in mind. Marketers can focus on what they know: their objective and their budget, and let AI define the audience, channels, products, offers, and content to achieve those goals. Kognitiv Ignite takes the guesswork out of delivering the right message to the right customer at the right time, empowering marketers to exceed their KPIs while maintaining their budget. By leveraging AI-powered automation, marketers can focus on driving strategy and innovation, while letting Kognitiv Ignite optimize their customer engagement in real time.
“We built Kognitiv Ignite to help marketers deliver highly curated experiences to their customers and profitable results to their business,” said Anthony Wintheiser, Chief Product Officer of Kognitiv. “Kognitiv Ignite’s outcome-based workflow, built on the back of the Kognition AI/ML engine, empowers marketers to engage millions of customers on an individualized basis in a way that is both relevant for the customer and incremental for the business. With Kognitiv Ignite, marketers will be able to build and run campaigns that are smarter and faster, while delivering higher sales and greater value to their business.”
Kognitiv Ignite is powered by Kognition, Kognitiv’s proprietary AI engine, that combines hundreds of AI/ML models including customer lifetime value, propensity, churn, and more, to deliver one-to-one personalization at scale. Kognition evaluates millions of attributes, predicts future customer behavior, and prescribes the perfect interaction for every customer to meet the brand’s predefined business goals. An integrated feedback loop that tracks attribution and incrementality ensures that customer engagement is optimized in real time to drive relevance and maximize ROI.
“At Kognitiv, we are dedicated to equipping marketers with the tools they need to drive not only customer engagement, but also substantial revenue growth,” said Tim Sullivan, Chief Executive Officer at Kognitiv. “With the launch of Kognitiv Ignite, our AI-native personalization software, we’re revolutionizing the way marketers approach customer engagement by letting them start with their defined goal and allowing the AI to steer them to success.”
Be among the first to learn more about Kognitiv Ignite, the AI co-pilot for your customer engagement strategy across owned channels. Get in touch with us or sign up to receive a personalized demo: https://www.kognitiv.com/landing-pages/ignite-demo.
About Kognitiv
Kognitiv inspires lifetime loyalty by helping brands build deeper relationships with their customers. Their intelligent, omnichannel SaaS platform delivers data-driven personalization across the entire customer lifecycle, enabling superior marketing effectiveness and consumer engagement.
In June 2020, Kognitiv and Aimia’s Loyalty Solutions business came together to become a global loyalty solutions leader. Today Kognitiv serves a broad portfolio of global brand customers and has employees in over 20 countries. With decades of loyalty solutions experience, Kognitiv has the history, the technology and the expertise to help marketing professionals stay ahead of the customer expectation curve.
Kognitiv’s largest investors include Aimia Inc., a publicly-traded holding company listed on the Toronto Stock Exchange (TSX: AIM).
Kognitiv has been named one of the top 100 most innovative martech companies in the world by The Martech Weekly.
